Non-inclusion cyclodextrin complexes

Details Non-inclusion cyclodextrin complexes Non-inclusion cyclodextrin complexes

2006-10-03

2006-10-03

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S557000, C514S060000, C514S772200, C514S772300, C514S773000, C514S777000, C514S779000, C514S781000, C514S338000, C514S026000, C536S103000, C536S120000, C536S122000, C536S046000, C424S493000, C424S440000, C424S500000

Reexamination Certificate

active

07115586

ABSTRACT:
The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with β-cyclodextrin in an aqueous complexation medium comprising β-cyclodextrin and a negatively- or positively-charged compound which forms an inclusion or non-inclusion complex with β-cyclodextrin and its inclusion complexes.

REFERENCES:
patent: 5024998 (1991-06-01), Bodor
patent: 5324718 (1994-06-01), Loftsson
patent: 5472954 (1995-12-01), Loftsson
patent: 5646131 (1997-07-01), Badwan et al.
patent: 6407079 (2002-06-01), Müller et al.
patent: 0149197 (1985-07-01), None
patent: 0 579 435 (1994-01-01), None
patent: 62 072628 (1987-04-01), None
T. Loftsson et al, “Interactions Between Preservatives and 2-Hydroxypropyl-β-Cyclodextrin”,Drug Development and Industrial Pharmacy, 18 (3), pp. 1477-1484 (1992), published by Marcel Dekker, New York, New York.
T. Loftsson et al, “Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization”,J. Pharm. Sci., 85, No. 10, pp. 1017-1025 (1996), published by American Pharmaceutical Association, Easton, PA.
T. Loftsson et al, “Cyclodextrins as Pharmaceutical Excipients”,Pharmaceutical Technology Europe, 9, pp. 26-34 (1997), published by Advanstar Communications, London, England.
R. Krishnamoorthy et al, “Complexation of Weak Acids and Bases with Cyclodextrins: Effects of Substrate Ionization on the Estimation and Interpretation of Association Constants”,Int'l. J. Pharm. Advances, vol. 1, No. 3, pp. 330-343 (1996), published by Technomic Pub. Co., Lancaster, PA.
T. Loftsson et al, “Effects of 2-hydroxypropyl-β-cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17β-estradiol”,Acta Pharm. Nord., vol. 1, No. 4, pp. 185-194 (1989), published by Swedish Pharmaceutical Press, Stockholm, Sweden.
E. Redenti et al, “Cyclodextrin Complexes of Salts of Acidic Drugs. Thermodynamic Properties, Structural Features, and Pharmaceutical Applications”,J. Pharm. Sci., vol. 90, No. 8, pp. 979-985 (2001), published by Wiley-Lisa, Inc., New York, New York.
E. Redenti et al, “Drug/Cyclodextrin/Hydroxy Acid Multicomponent Systems. Properties and Pharmaceutical Applications”,J. Pharm. Sci., vol. 89, No. 1, pp. 1-8 (2000), published by Wiley-Lisa, Inc., New York, New York.
T. Loftsson et al, “The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin”,Int. J. Pharmaceutics, 163, pp. 115-121 (1998), published by Elsevier/North-Holland Biomedical Press, Amsterdam, The Netherlands.
B. Pose-Vilarnovo et al,Journal of Thermal Analysis and Calorimetry, vol. 68, pp. 657-667 (2002), published by Kluwer Academic Publishers; Dordrecht, The Netherlands.
T. Loftsson et al, “The Influence of Water-Soluble Polymers and pH on Hydroxypropyl-β-Cyclodextrin Complexation of Drugs”,Drug Devel. Ind. Pharm., 22(5), pp. 401-405 (1996), published by Marcel Dekker, New York, New York.
D. Attwood et al,Surfactant Systems, Their Chemistry, Pharmacy and Biology, pp. 361-365 (1983), published by Chapman and Hall, London, England.
Remington's Pharmaceutical Sciences, 18th edition, ed. Alfonso R. Gennaro, pp. 291-294 (1990), published by Mack Publishing Company, Easton, PA.
Martin et al,Physical Pharmacy. Physical Chemical Principles in Pharmaceutical Sciences, 3rd edition, pp. 592-638 (1983), published by Lea & Febiger, Philadelphia, PA.
Florence et al,Physicochemical Principles of Pharmacy, 2nd edition, pp. 281-334 (1988), published by Chapman and Hall, New York, New York.
Loftsson et al, “Cyclodextrins and drug permeability through semi-permeable cellophane membranes”,International Journal of Pharmaceutics, 232, pp. 35-43 (2002), published by Elsevier/North-Holland Biomedical Press, Amsterdam, the Netherlands.
T. Loftsson et al, “The Effects of Cyclodextrins on Transdermal Delivery of Drugs”,Eur. J. Pharm. Biopharm., 37 (1), pp. 30-33 (1991), published by Wissenschaftliche Verlagsgesellschat mbH, Stuttgart, Germany.
Loftsson, Thorsteinn et al., “Cyclodextrin complexation of NSAIDS: Physichochemical characteristics.” European Journal of Pharmaceutical Sciences, vol. 1, No. 2, 1993, pp. 95-101, Elsevier Science B.V., Amsterdam, the Netherlands.
Loftsson, Thorsteinn et al., “The effect of polyvinylpyrrolidone and hydroxypropyl methylcellulose on HP-beta-CD complexation of hydrocortisone and its permeability through hairless mouse skin.” 1994, European Journal of Pharmaceutical Sciences, vol. 2, No. 4, pp. 297-301, Elsevier Science B.V., Amsterdam, the Netherlands.
Derwent Abstracts, WPI Acc No.: 1987-132517/198719, abstract of JP 62 072628 (Apr. 3, 1987).

Affiliated with

Also associated with

Rating

Non-inclusion cyclodextrin complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-inclusion cyclodextrin complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-inclusion cyclodextrin complexes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3682264